{"organizations": [], "uuid": "8ea4fc8f5ad7d83434de1475419daf94171f7875", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-avid-bioservices-oncologie-enter-i/brief-avid-bioservices-oncologie-enter-into-asset-assignment-purchase-agreement-for-avids-ps-targeting-program-including-bavituximab-idUSFWN1Q211S", "country": "US", "domain_rank": 408, "title": "BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T15:14:00.000+02:00", "replies_count": 0, "uuid": "8ea4fc8f5ad7d83434de1475419daf94171f7875"}, "author": "", "url": "https://www.reuters.com/article/brief-avid-bioservices-oncologie-enter-i/brief-avid-bioservices-oncologie-enter-into-asset-assignment-purchase-agreement-for-avids-ps-targeting-program-including-bavituximab-idUSFWN1Q211S", "ord_in_thread": 0, "title": "BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab", "locations": [], "entities": {"persons": [{"name": "purcha", "sentiment": "negative"}, {"name": "oncologie", "sentiment": "none"}], "locations": [], "organizations": [{"name": "avid bioservices inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "avid's ps-targeting program including bavituximab reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 16 PM / Updated 6 minutes ago BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Avid Bioservices Inc: \n* AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB \n* AVID BIOSERVICES INC - ‍AVID WILL RECEIVE $8 MILLION IN UPFRONT PAYMENTS FROM ONCOLOGIE PAID OVER A PERIOD OF SIX MONTHS FROM EXECUTION DATE OF AGREEMENT​ \n* AVID BIOSERVICES INC - ‍AVID WILL BE ELIGIBLE TO RECEIVE UP TO $95 MILLION IN DEVELOPMENT, REGULATORY AND COMMERCIALIZATION MILESTONES​ \n* AVID BIOSERVICES - ‍ONCOLOGIE TO BE RESPONSIBLE FOR FUTURE RESEARCH, DEVELOPMENT & COMMERCIALIZATION OF BAVITUXIMAB, RELATED INTELLECTUAL PROPERTY COSTS​ \n* AVID BIOSERVICES INC - ‍ONCOLOGIE WILL ENTER INTO DEAL WITH AVID FOR FUTURE CONTRACT DEVELOPMENT AND MANUFACTURING ACTIVITIES IN SUPPORT OF BAVITUXIMAB​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-12T15:14:00.000+02:00", "crawled": "2018-02-12T15:35:51.011+02:00", "highlightTitle": ""}